Todos Medical

Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The company's Todos Biochemical Infrared Analyses comprise proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test is a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies.

Todos Medical has raised $3.45M in total funding across 4 rounds. The company is currently at the Public stage. Key investors include The Yozma Group, Undisclosed Investor(s).

Todos Medical operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening, with core technologies in Biologicals, Sensing, Infrared. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology, Healthcare, Providers, Laboratories.

Todos Medical is based in Derech Menachem Begin 121, Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.